DOI: 10.1128/JCM.00717-19
Article Information
PubMed
Published By
History
- Received May 8, 2019
- Returned for modification June 2, 2019
- Accepted August 9, 2019
- Published online October 23, 2019.
Copyright & Usage
Copyright © 2019 Ng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Editors and / or Reviewers
- Geoffrey A. Land, Editor, Carter BloodCare and Baylor University Medical Center
Article Versions
- Accepted Manuscript version (August 14, 2019).
- You are viewing the most recent version of this article.
Author Information
- Kamela C. S. Nga,b,c,
- Philip Supplyd,
- Frank G. J. Cobelensb,
- Cyril Gaudine,
- Julian Gonzalez-Martinc,
- Bouke C. de Jonga and
- Leen Rigoutsa,f
- aMycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
- bDepartment of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam UMC, Location Academic Medical Center, Amsterdam, The Netherlands
- cServei de Microbiologia, Centre de Diagnòstic Biomèdic, Hospital Clínic, Institut de Salut Global de Barcelona, Universitat de Barcelona, Barcelona, Spain
- dUniversity Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019, UMR 8204, Center for Infection and Immunity of Lille (CIIL), Lille, France
- eGenoscreen, Lille, France
- fDepartment of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Address correspondence to Kamela C. S. Ng, kng{at}itg.be.
Citation Ng KCS, Supply P, Cobelens FGJ, Gaudin C, Gonzalez-Martin J, de Jong BC, Rigouts L. 2019. How well do routine molecular diagnostics detect rifampin heteroresistance in Mycobacterium tuberculosis? J Clin Microbiol 57:e00717-19. https://doi.org/10.1128/JCM.00717-19.
